Bayesian predictive probability based on a bivariate index vector for single-arm phase II study with binary efficacy and safety endpoints

Takuya Yoshimoto¹, Satoru Shinoda², Kouji Yamamoto² and Kouji Tahata³

¹Biometrics Department, Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, 103-8324, Japan ²Department of Biostatistics, Yokohama City University School of Medicine, Yokohama City, Kanagawa, 236-0004, Japan

³Department of Information Sciences, Faculty of Science and Technology, Tokyo University of Science, Noda City, Chiba, 278-8510, Japan

E-mail: yoshimoto.takuya61@chugai-pharm.co.jp, shinoda.sat.cg@yokohama-cu.ac.jp, kouji_y@yokohama-cu.ac.jp and kouji_tahata@rs.tus.ac.jp

Last update: May 17, 2023

Abstract

In oncology, phase II studies are crucial for clinical development plans, as they identify potent agents with sufficient activity to continue development in the subsequent phase III trials. Traditionally, phase II studies are single-arm studies, with an endpoint of treatment efficacy in the short-term. However, drug safety is also an important consideration. Thus, in the context of such multiple-outcome design, predictive probabilities-based Bayesian monitoring strategies have been developed to assess if a clinical trial will show a conclusive result at the planned end of the study. In this paper, we propose a new simple index vector for summarizing the results that cannot be captured by existing strategies. Specifically, for each interim monitoring time point, we calculate the Bayesian predictive probability using our new index, and use it to assign a go/no-go decision. Finally, simulation studies are performed to evaluate the operating characteristics of the design. This analysis demonstrates that the proposed method makes appropriate interim go/no-go decisions.

Keywords: Bayesian monitoring, efficacy and toxicity endpoints, index vector, predictive probability, single-arm phase II study.

1 Introduction

In oncology, the primary objective of phase II clinical trial is commonly to evaluate the preliminary efficacy of a new treatment, in order to identify agents with sufficient activity to continue development in the subsequent phase III trials. Accordingly, phase II studies play an important role in whole of clinical development plan. Typically, phase II oncology studies follow a single-arm study, with an endpoint of treatment efficacy in the short-term. Specifically, objective response based on Response Evaluation Criteria in Solid Tumors (Eisenhauer et al., 2009) (RECIST) is commonly used as primary endpoint in terms of the treatment efficacy. Moreover, these studies routinely implement futility monitoring and interim go/no-go decision making to protect patients against ineffective treatments. Numerous frequentist and Bayesian designs have been proposed for single-arm phase II studies. From the perspective of single-outcome designs, the well-known frequentist design is Simon's two-stage design (Simon, 1989), which minimizes the maximum sample size or the expected sample size under the null hypothesis that the

treatment is ineffective while controlling for type I and II error rates. In the Bayesian framework, Thall and Simon (1994a) provided practical guidelines on implementing an adaptive single-arm phase II study, which involved updating the Bayesian posterior probability after observing the data. Lee and Liu (2008) developed predictive probability-based Bayesian monitoring for a single-arm phase II clinical trial. This study evaluated the probability of achieving the desired outcome at the planned end of the trial, conditional on accumulated interim data. In addition, Sambucini (2021b) extended the designs of Lee and Liu (2008) by considering the uncertainty of historical control. Further, Yin et al. (2012) used the predictive probability to construct a randomized phase II design based on Bayesian adaptive randomization. A predictive distribution approach considers decisions in the final analysis based on data that will be available in the future, whereas a posterior distribution approach relies only on data at intermediate time points. Definitive conclusions are often difficult to obtain from data at interim time points; therefore, the effectiveness of the final analysis demands that consideration be given to data that will be available in the future. As such, predictive distributions are easy to interpret as decision-making at the time of the final analysis. Saville et al. (2014) and Berry (2004) have summarized the advantages of using predictive distributions, which have been used across several clinical trials were designed using predictive probability (see, e.g., Buzdar et al., 2005; Domchek et al., 2020; Murai et al., 2021; Tap et al., 2012).

From the perspective of a multiple-outcome design, consideration of drug safety is assigned primary importance. For example, Bryant and Day (1995) introduced a two-stage design with efficacy and toxicity instead of a single efficacy endpoint. Thall et al. (1995) extended the designs of Thall and Simon (1994a) from single to multiple outcomes, which accounted for the distinction between adverse and desirable outcomes. Brutti et al. (2011) also presented a Bayesian posterior probability-based approach that imposed a restrictive definition of the overall goodness of the therapy by controlling the number of responders who simultaneously do not experience adverse toxicity. Similarly, Sumbucini (2019) proposed a Bayesian decision-making method based on predictive probability, involving both efficacy and safety, with binary outcomes. Specifically, the decision-making was based on the marginal probability of experiencing toxicity and on the joint probability of simultaneously experiencing a response to the therapy without experiencing toxicity. Other studies have also focused on both efficacy and safety with binary outcomes (Zhou et al., 2017; Guo et al., 2020; Sambucini, 2021a). From the regulatory aspect of drug development, a guideline on Complex Innovative Trial Design has been issued by FDA (Guidance for industry, 2020), and the use of Bayesian is mentioned in the guideline. Recently, Ruberg et al. (2023) also stated that the widespread adoption of Bayesian approaches has the potential to be the most impactful tool for improving the development of new medicines. Additionally, from the perspective of finding an optimal dose, Shah et al. (2021) pointed out that for targeted drug and biological therapies, dose selection should be informed by exposure-response, efficacy, and safety data from early trials, rather than automatically selecting the maximum tolerated dose (see also the FDA Draft Guidance for Industry, 2023). Therefore, it is expected that Bayesian statistics with multiple-outcome designs will gradually be used by a majority of clinical trials in the near future.

In this paper, we employ Bayesian single-arm designs with binary efficacy and safety outcomes that are based on predictive probability, an approach that is consistent with that prescribed by Brutti et al. (2011) and Sumbucini (2019). Specifically, for the purpose of exemplification, we use an artificial dataset in Table 1, with a small sample size.

[Tables 1(a) and (b) about here.]

Table 1(a) is more promising than Table 1(b), as the joint probability of simultaneously experiencing efficacy and toxicity is substantially different between Tables 1(a) and 1(b). However, because of the same marginal probability of experiencing toxicity and the joint probability of simultaneously experiencing efficacy and safety, Brutti et al. (2011) and Sumbucini (2019) could not capture these differences, as shown in Tables 1(a) and (b). Accordingly, we consider the probability of simultaneously being a non-responder to the therapy while experiencing toxicity. In this case, the natural idea is to consider the simultaneous distribution of these probabilities; however, the elicitation of such a simultaneous distribution is complicated because the marginal probability of toxicity and the probability of simultaneously being a non-responder to the therapy while experiencing toxicity are not mutually exclusive. However, computational burden is a well-known issue while calculating predictive probability (Saville et al., 2014); thus, constructing a simple index to summarize the results is desirable. Therefore, we consider an approach for making a decision by assuming the worst situation for the potential effect of a treatment and measuring the deviation from that situation. As the worst situation can be expressed as a particular probability distribution, it is natural to consider an index based on the difference (or similarity) between two probability distributions. Various divergences represented by the Kullback-Leibler Divergence (KLD) have been proposed for two distributions of a discrete random variable. In this paper, we focus on the Jensen Shannon Divergence (Lin, 1991) (JSD) as we address the specific situation that KLD cannot generally be defined, and propose a method to evaluate adaptively using a new index based on JSD. JSD has been used in many fields and has been applied in the design of clinical trials (see, e.g., Fujikawa et al., 2020). As efficacy and toxicity may not be independent, a method that accounts for their joint distribution would be appropriate in this situation. Therefore, we do not consider marginal models that lead to a decision that is independently obtained through the conjunction of two marginal distributions. In addition, we consider adding uncertainty to the historical control data using a prior distribution to the proposed methodology.

The remainder of this article is organized as follows: in Section 2, we introduce the notation and propose a bivariate index to summarize data from clinical trials with binary outcomes. Here, we describe an asymptomatic approach, in addition to the Monte Carlo approach, to calculate the proposed predictive probability. In addition, we present a decision-making framework based on predictive probability using the proposed index. A detailed illustration of the proposed procedure for each approach is presented in Section 3. Section 4 describes the properties of the asymptotic approach using different hypothetical situations. In Section 5, we present the results of simulation studies aimed at evaluating the operating characteristics of the proposed methodology. Finally, Section 6 presents a discussion along with the design parameter optimization. All the computations presented in this paper were performed using R programming (R Core Team 2023).

2 Methods

2.1 New bivariate index vector

We consider a single-arm phase II trial based on binary endpoints that represent the efficacy and toxicity data that are summarized in the 2×2 square contingency tables in Table 2, with the corresponding cell probabilities $\mathbf{p} = (p_{11}, p_{12}, p_{21}, p_{22})'$ such that $\sum_i \sum_j p_{ij} = 1$, where \prime denotes the transpose.

[Table 2 about here.]

Next, we consider the worst situation for the potential effect of a treatment by controlling the number of

non-responders who simultaneously experience adverse toxicity. To examine this structure, we regard the efficacy as the ratio of p_{12} to p_{21} , along with the marginal probability of toxicity, and consider an approach where a decision on the potential effect of a drug is made by measuring the distance from a probability distribution. Let $\mathbf{q} = (q_{11}, q_{12}, q_{21}, q_{22})'$ be discrete finite bivariate probability distribution as well as \mathbf{p} . Furthermore, we denote $p_{ij}^* = p_{ij}/(p_{ij} + p_{ji})$ and $q_{ij}^* = q_{ij}/(q_{ij} + q_{ji})$ for i = 1, 2; j = 1, 2, respectively. From the perspective of efficacy, we define the worst case is expressed as a structure with $q_{12}^* = 0$, assuming that efficacy does not depend on a diagonal cell. However, from the perspective of toxicity, we define the worst case is expressed as a structure with $q_{11} = 1$. Then we consider measuring the deviation from these situations. As the worst situation can be expressed as a particular probability distribution, it is natural to consider an index based on the difference (or similarity) between two probability distributions. Then the KLD is used as it is the standard approach to calculating the difference between probability distributions. The KLD between \mathbf{p} and \mathbf{q} is shown as follows:

$$KLD(\boldsymbol{p}:\boldsymbol{q}) = \sum_{i} \sum_{j} p_{ij} \log \frac{p_{ij}}{q_{ij}}.$$

Notably, KLD(p:q) is undefined if $q_{ij}=0$ and $p_{ij}\neq 0$ for at least one i,j. This means that the distribution p must be absolutely continuous with respect to the distribution q for KLD(p:q) to be defined (Lin, 1991). However, we need to consider the probability distribution q includes $q_{12}^*=0$ and $q_{11}=1$ (then $q_{12}=0$) from the perspectives of efficacy and toxicity, respectively. As such, KLD cannot generally be defined in this situation; thus, to address this issue, we focus on the JSD as a measure of the difference between two distributions. JSD(p:q) is a well-grounded symmetrization of the KLD defined as

$$JSD(\mathbf{p} : \mathbf{q}) = \frac{1}{2} \sum_{i} \sum_{j} \left(p_{ij} \log \frac{2p_{ij}}{p_{ij} + q_{ij}} + q_{ij} \log \frac{2q_{ij}}{p_{ij} + q_{ij}} \right).$$

A notable feature of JSD(p:q) is that this divergence requires that p and q be absolutely continuous with respect to each other. In addition, the JSD is always upper bounded by log 2. Using this divergence, we propose new indexes for summarizing efficacy Φ_{eff} and toxicity Φ_{tox} as follows:

$$\begin{split} &\Phi_{eff} = \frac{1}{2\log 2} \left(p_{12}^* \log 2 + p_{21}^* \log \frac{2p_{21}^*}{p_{21}^* + 1} + \log \frac{2}{p_{21}^* + 1} \right), \\ &\Phi_{tox} = \frac{1}{2\log 2} \left(p_{\cdot 2} \log 2 + p_{\cdot 1} \log \frac{2p_{\cdot 1}}{p_{\cdot 1} + 1} + \log \frac{2}{p_{\cdot 1} + 1} \right). \end{split}$$

The index Φ_{eff} : (i) lies between 0 and 1; (ii) $\Phi_{eff} = 0$ if and only if the conditional probability $p_{12}^* = 0$; and (iii) $\Phi_{eff} = 1$ if and only if $p_{12}^* = 1$. Similarly, the index Φ_{tox} : (i) lies between 0 and 1; (ii) $\Phi_{tox} = 0$ if and only if the marginal probability $p_{.1} = 1$; and (iii) $\Phi_{tox} = 1$ if and only if $p_{.1} = 0$. This measure expresses the degree of departure from the most adverse case toward the most promising case in terms of efficacy and toxicity, respectively. Considering the joint association structure of Φ_{eff} and Φ_{tox} , we propose the following bivariate index vector:

$$\mathbf{\Phi} = \left(\Phi_{eff}, \Phi_{tox}\right)',\tag{1}$$

where Φ is a 2×1 vector. To derive the posterior distribution of Φ , an approach based on the Monte Carlo method (see, e.g., Spiegelhalter, 2004, p.103) is possible; however, this causes a substantial computational burden due to the complexity of the predictive distribution (see, Section 2.2). Thus, we derive an asymptotic distribution for the posterior distribution of the proposed index vector. To estimate the indexes, $\hat{\Phi}$ is given by Φ with Φ_{eff} and Φ_{tox} replaced by $\hat{\Phi}_{eff}$ and $\hat{\Phi}_{tox}$ using \hat{p} as a consistent estimator

of p. Given a fixed sample size of N, the posterior distribution of $\sqrt{N}(\hat{\Phi} - \Phi)$ has an asymptotically a bivariate normal distribution with a mean of zero and the following covariance matrix:

$$\Sigma = \begin{pmatrix} \sigma_{11} & \sigma_{12} \\ \sigma_{21} & \sigma_{22} \end{pmatrix},\tag{2}$$

where $\sigma_{12} = \sigma_{21}$. Further, the elements σ_{11} , σ_{12} and σ_{22} are expressed as follows (for details, see Appendix A):

$$\begin{split} \sigma_{11} &= \left[\frac{1}{2\log 2}\log\left(\frac{p_{21}^*}{p_{21}^*+1}\right)\right]^2\frac{p_{12}^*p_{21}^*}{p_{12}+p_{21}},\\ \sigma_{12} &= \left(\frac{1}{2\log 2}\right)^2p_{12}^*p_{21}^*\log\left(\frac{p_{21}^*}{p_{21}^*+1}\right)\log\left(\frac{p_{\cdot 1}}{p_{\cdot 1}+1}\right),\\ \sigma_{22} &= \left[\frac{1}{2\log 2}\log\left(\frac{p_{\cdot 1}}{p_{\cdot 1}+1}\right)\right]^2p_{\cdot 1}p_{\cdot 2}. \end{split}$$

2.2 Predictive monitoring based on proposed index vector

Next, we represent the efficacy and toxicity of an experimental treatment, E, and assume that a standard treatment, S is collected as historical control data. The observed outcomes of participants who have entered the trial thus far to E are denoted by $\mathbf{X} = (X_{11}, X_{12}, X_{21}, X_{22})'$, which come from a multinomial distribution with the sum of the current data n and the parameter \mathbf{p}_E . In addition, the maximum sample size planned for the entire trial of E is denoted by N_{max} . The multinomial distribution belongs to the exponential family and its natural conjugate prior density is a Dirichlet distribution. Here, we denote the t = E, S as the index treatment. We then introduce a Dirichlet prior for $\mathbf{p}_t = (p_{t,11}, p_{t,12}, p_{t,21}, p_{t,22})'$,

$$p_t | \alpha_t \sim \text{Dir}(\alpha_t)$$
,

where $\alpha_t = (\alpha_{t,11}, \alpha_{t,12}, \alpha_{t,21}, \alpha_{t,22})'$ is the vector of hyperparameters such that $\alpha_{t,ij} > 0$, $\forall i, j$. From the conjugate analysis, given the observed outcome \boldsymbol{x} , we obtain the following posterior distribution of \boldsymbol{p}_E

$$p_E | \alpha_E, x \sim \text{Dir} (\alpha_E + x)$$
.

Let $\mathbf{Y} = (Y_{11}, Y_{12}, Y_{21}, Y_{22})'$ be the random efficacy and safety data for potential m future patients, i.e., $n + m = N_{max}$. At the end of the trial, when the data become available for all the N_{max} patients with data $\mathbf{Y} = \mathbf{y}$ collected, we can construct the following posterior distribution of \mathbf{p}_E

$$oldsymbol{p}_E | oldsymbol{lpha}_E, oldsymbol{x}, oldsymbol{y} \sim \mathrm{Dir} \left(oldsymbol{lpha}_E + oldsymbol{x} + oldsymbol{y} + oldsymbol{y}
ight).$$

For the interim analysis, data y are not observed; thus we consider a posterior predictive distribution of Y, given α_E , x. This is a Dirichlet compound multinomial distribution with the following probability mass function:

$$f_m(\boldsymbol{y}|\boldsymbol{\alpha}_E,\boldsymbol{x}) = \frac{\Gamma(m+1)}{\prod_i \prod_j \Gamma(y_{ij}+1)} \frac{\Gamma\left(\sum_i \sum_j \alpha_{E,ij} + x_{ij}\right)}{\Gamma\left(\sum_i \sum_j \alpha_{E,ij} + x_{ij} + y_{ij}\right)} \prod_i \prod_j \frac{\Gamma\left(\alpha_{E,ij} + x_{ij} + y_{ij}\right)}{\Gamma\left(\alpha_{E,ij} + x_{ij}\right)},$$

where $\Gamma(\cdot)$ is a Gamma function. See Appendix B for details on the elicitation of Dirichlet compound multinomial probability mass function. Here, we consider the number of patterns in \mathbf{Y} . This problem can be formulated to obtain the total number of combinations when the range of each cell is equally [0, m]

under the condition that the sum of the observed frequencies is m. In general, the number of solutions is determined by the coefficient of z^m in a generating function (Hankin, 2007) $\prod_{i=1}^T \sum_{j=0}^{f_i} z^j$, where

$$\sum_{i=1}^{T} y_i = m \quad (0 \le y_i \le f_i),$$

and T is the number of cells, i.e., T = 4, $f_i = m$ for all i. Notably, the number of patterns becomes quite huge when there are many m future participants. Based on the data obtained at the end of the trial (i.e., when the maximum sample size is reached), an interim go/no-go decision is made based on the following probability:

$$\Pr\left(\mathbf{\Phi}_{E} - \mathbf{\Phi}_{S} > \boldsymbol{\delta}_{0} \middle| \boldsymbol{\alpha}_{S}, \boldsymbol{\alpha}_{E}, \boldsymbol{x}, \boldsymbol{y}\right) \geq \lambda,\tag{3}$$

where λ is a pre-specified probability threshold, $\boldsymbol{\delta}_0$ is the minimally acceptable increment, and $\boldsymbol{\Phi}_t$ is obtained by replacing \boldsymbol{p} with \boldsymbol{p}_t from Equation (1). Unless otherwise specified, $\boldsymbol{\delta}_0$ is considered as $\boldsymbol{0} = (0,0)'$. To calculate Equation (3), we obtain the asymptotic distribution of the difference between $\boldsymbol{\Phi}_E$ and $\boldsymbol{\Phi}_S$: Owing to the properties of the multivariate normal distribution, $\hat{\boldsymbol{\Phi}}_E - \hat{\boldsymbol{\Phi}}_S - (\boldsymbol{\Phi}_E - \boldsymbol{\Phi}_S)$ also has an asymptotically bivariate normal distribution with a zero mean vector and covariate matrix:

$$\frac{1}{N_{max} + \sum_{i} \sum_{j} \alpha_{E,ij}} \mathbf{\Sigma}_{E} + \frac{1}{\sum_{i} \sum_{j} \alpha_{S,ij}} \mathbf{\Sigma}_{S}, \tag{4}$$

where Σ_t is obtained by replacing p with p_t from Equation (2). To estimate the index vector Φ_E and the covariance matrix Σ_E , the following Bayesian estimator is plugged in as a consistent estimator:

$$\hat{p}_{E,ij} = \frac{\alpha_{E,ij} + x_{ij} + y_{ij}}{\sum_{i} \sum_{j} \alpha_{E,ij} + N_{max}}.$$

On the other hand, for Φ_S and Σ_S , we plugged in $\hat{p}_{S,ij} = \alpha_{S,ij}/\sum_i \sum_j \alpha_{S,ij}$. This is because, while the pattern including zero counts is considered in the predictive distribution, the existence of zero counts makes the estimation of the asymptotic covariance matrix theoretically impossible. Although the range of the proposed indexes is defined as [0,1], this provides the range of the estimate as (0,1).

Subsequently, $I(\cdot)$ is considered an indicator that maps the elements of the subset to one, and all other elements to zero. At the interim monitoring, we can compute the predictive probability that the experimental drug will be declared sufficiently promising at the planned end of the trial using the following equation:

$$PP = \sum_{\mathbf{y}} f_m(\mathbf{y}|\boldsymbol{\alpha}_E, \mathbf{x}) I\left(\Pr\left(\boldsymbol{\Phi}_E - \boldsymbol{\Phi}_S > \boldsymbol{\delta}_0|\boldsymbol{\alpha}_S, \boldsymbol{\alpha}_E, \mathbf{x}, \mathbf{y}\right) \ge \lambda\right). \tag{5}$$

This is interpreted as the weighted average of the indicators of a successful trial at the end of the trial based on the probability of the Dirichlet-multinomial distribution. A high PP indicates that the experimental treatment is likely to be efficacious by the end of the study, given the current data, whereas a low PP suggests that the experimental treatment may not be sufficient activity. In line with Lee and Liu (2008) and Sumbucini (2019), the decision rules can be constructed as follows:

- if $PP < \theta_L$, then stop the trial and claim that the experimental treatment is not sufficiently successful;
- if $PP > \theta_U$, then stop the trial and claim that the experimental treatment is sufficiently successful;
- otherwise, continue enrolling patients until the maximum sample size is reached.

Typically, we choose θ_L as a small positive number and θ_U as a large positive constant, both between 0 and 1. $PP < \theta_L$ indicates that the trial is unlikely to show the desired performance in terms of efficacy

and safety at the end of the trial given the current information. On the other hand, when $PP > \theta_U$, the current data suggest a high probability of concluding that the experimental treatment is efficacious at the end of the study. Given the nature of single-arm phase II studies, we set $\theta_U = 1$ throughout this paper. This is because there is no ethical concern about accruing additional participants for a specific situation in which early results appear positive, thereby increasing the precision of the profile of efficacy and safety data (Green et al., 2012, Section 5.1.1).

3 Numerical application

Herein, we demonstrate the process of calculating the predictive probability using both the Monte Carlo and asymptomatic approaches. Assuming that the maximum sample size of the study N_{max} is 30 and that the observed data in Table 1(a) are the current data. For the hyperparameter vector of E, Jeffrey's prior is adopted throughout this paper, as it is often used as a non-informative prior, and will allow the likelihood to dominate the posterior distribution. Importantly, Brutti et al. (2011) and Sumbucini (2019) derived the reference prior, and that the Jeffery's prior in the Dirichlet distribution is corresponding to a 1-group reference prior (Berger and Bernardo, 1992). In contrast, we require an informative prior of S, based on a combination of historical control data and clinical experience. Therefore, the values of $\alpha_E = (0.5, 0.5, 0.5, 0.5)$ and $\alpha_S = (10, 9, 11, 30)$ are set in this section. For the Monte Carlo approach, we set the number of repeat simulations to 10,000. Hereafter, the distribution using the Monte Carlo approach is referred to as the simulation distribution in this paper. Here, we assume that $\mathbf{y} = (0, 3, 2, 0)$ as a result of the future participants. Then, the bivariate index vector of the difference between Φ_E and Φ_S is estimated (0.397, 0.106)'. Figures 1(a) and (b) show the simulation distributions of Φ_E , Φ_S and that of the difference using the Monte Carlo approach, whereas Figures 2(a) and (b) show those of the asymptotic distribution.

For the asymptotic approach, the estimated covariance matrix of the difference Σ_d given by Equation (4), replacing p_t with \hat{p}_t is as follows:

$$\hat{\Sigma}_d = \begin{pmatrix} 0.024 & 0.010 \\ 0.010 & 0.011 \end{pmatrix}.$$

To shorten the notation, we denote the left side of Equation (3) by B(Y) in this section. Then, B(Y) is calculated to be 0.8457 and 0.8378 using the Monte Carlo and asymptotic approaches, respectively.

Next, we consider all the possible responses Y, including y = (0, 3, 2, 0), among the potential m = 5 future participants; that is, all the possible entries of 2×2 square contingency table consistent with a total equal to 5, i.e., $N_{max} = 30$. When the threshold λ is set to 0.80, Tables 3 and 4 present the proposed predictive probability based on Monte Carlo and asymptotic approaches, respectively.

In Tables 3 and 4, we enumerate all the possible values of Y, and the second column provides its posterior predictive probability computed by $f_m(y)$. For each of item, we show its posterior predictive probability of declaring the treatment promising at the end of the trial for both the Monte Carlo and asymptotic approaches. A further column provides the value of the indicator, which is equal to 1 if the corresponding

posterior probability B(Y) exceeds λ , otherwise 0. Simply by summarizing it, we obtain the predictive probability of interest. Thus, the values of PP given by Equation (5) are 0.907 for both the Monte Carlo and asymptotic approaches, respectively. For the data in Table 1(b), we can obtain the values of PP as 0.743 and 0.732 for the Monte Carlo and asymptotic approaches, respectively.

4 Properties of asymptotic approach

This section presents an approximation of this asymptotic approach. To evaluate the performance of the asymptotic approach, various probability scenarios are considered. First, the null hypothesis (H_0) and the alternative hypothesis (H_1) are set to visualize the behavior of each approach as presented by these specific hypotheses:

$$H_0: \Phi_E = \Phi_S \quad \text{vs} \quad H_1: \Phi_E \neq \Phi_S.$$

We assume that $P_E = (0.15, 0.30, 0.15, 0.40)$ under H_0 , whilst $P_E = (0.10, 0.50, 0.05, 0.35)$ under H_1 , and the threshold λ is set to 0.80. Figure 3 illustrates the predictive probabilities with various values of n for the number of current data of E and α_S . In total, nine patterns of α_S are obtained by setting $\sum_i \sum_j \alpha_{S,ij}$ from 60 to 220 by 20, with $\mathbf{p}_S = (0.15, 0.30, 0.15, 0.40)$. In addition, four patterns are obtained in terms of the current amount of data n from 20 to 80 by 20, and the remaining data of E (m) is set to 20 participants. Figure 3(a) and Figure 3(b) show the results under H_0 and H_1 , respectively.

Figures 3(a) and (b) demonstrate that even if the number of current participants n in the clinical trial is 20, the asymptotic approach could well approximate the results of the Monte Carlo approach. However, since the approximation depends on the precision, i.e., variance of the distribution, care should be taken when the amount of information contributing to S, such as the sample size of historical control data, is quite small. This is because the probability of success may not increase above a certain level irrespective of the size of the single-arm phase II study. This is evident from the asymptotic distribution of the difference given in Equation (4). Therefore, optimization of the tuning parameter is important (see Section 6).

5 Operating characteristics of the proposed design

In this section, we use a simulation to empirically investigate the performance of the proposed Bayesian interim procedure based on an asymptotic approach in terms of frequentist operating characteristics. As shown in Section 2, we set $\theta_U = 1$ such that the trial can be terminated only because of low efficacy or excessive toxicity, and set $\theta_L = 0.001$. In addition, we set $\alpha_E = (0.5, 0.5, 0.5, 0.5, 0.5)$ as Jeffrey's prior to have a vague prior. For hyperparameter of S, we set $\alpha_S = (30, 60, 30, 80)$ with $\sum_i \sum_j \alpha_{S,ij} = 200$ as an informative prior based on the results shown in Section 4. For reference, we also describe that the widths of the 95% credible interval for the marginal distributions of Φ_{eff} and Φ_{tox} are estimated as 0.195 and 0.134, respectively, according to the asymptotic approach. Furthermore, see, e.g., Thall and Simon (1994b), Zohar et al. (2008), and Hirakawa et al. (2018) for examples of the width of the credible interval. In addition, the threshold λ is set to 0.80. We assume that the first interim analysis is conducted after observing $N_{min} = 10$ participants, and subsequently, data are monitored using cohorts of size one or five until the maximum sample size $N_{max} = 40$ is reached. To evaluate the performance of the designs, we considered the following three metrics: (i) The percentage of early terminations (PET) is defined as the percentage of trials that are terminated early. (ii) The percentage of rejection of the

null hypothesis (PRN) is defined as the percentage of the simulated trials in which H_0 is rejected, i.e., the frequency of simulated trials that are not stopped before the maximum sample size is reached. The PRN is the type I error rate (or power) when H_0 is (or is not) true, or the percentage of claims that the experimental treatment is effective. (iii) The actual sample size is defined as the average sample size (ASS) actually used in 10,000 simulated trials.

5.1 Simulation study 1

We first evaluate the operating characteristics of the proposed Bayesian interim procedure for comparison with Sambucini (2019) and to evaluate a realistic and practical setting with reference to the settings in Sambucini (2019) and Zhou et al. (2017). Since the proposed method is dependent on the precision of S, it can be interpreted as a comparison with the case in which the design of Sambucini (2019) is applied when the relevant information, such as α_S is available before the onset of the trial. Table 5 lists the operating characteristics of the proposed designs, summarized by the empirical probabilities of PET, PRN, and ASS.

[Table 5 about here.]

Consider the scenarios 1 and 2 presented in Table 5. Both are characterized by the true joint probability of efficacy and safety p_{12} being equal; however, the true joint probability of non-efficacy and toxicity p_{21} and the marginal probability of toxicity $p_{\cdot 1}$ are different. Thus, compared to scenario 2, scenario 1 is a slightly better setting. As a result, scenario 1 has a lower PET and higher PRN and ASS than scenario 2 for each cohort size. In addition, considering scenarios 1 and 4, these scenarios should have almost the same setting, as the true ratios of p_{12} and p_{21} are the same and true p_{11} is the same as well. Consequently, both groups are characterized as having the almost the same PET, PRN, and ASS for each cohort size. In contrast, scenario 5 is obviously inferior to scenario 1, because both have the same true p_{21} and true $p_{.1}$, but the true p_{12} is different. Thus, scenario 1 has a far lower PET and higher PRN and ASS than scenario 5 for each cohort size. On the other hand, consider the last two scenarios presented in Table 5, i.e., scenarios 9 and 10. Scenario 10 is slightly more promising situation with same true $p_{\cdot 1}$ and different true ratio of p_{12} and p_{21} , as well as scenarios 6 and 7. Consequently, scenario 9 has a higher PET and lower PRN and ASS than scenario 10. Similarly, scenario 6 has a higher PET and lower PRN and ASS than scenario 7. For the cohort size, PRN and ASS increase, and PET decreases overall in cohort size 5 compared with cohort size 1. In our simulation study, comparisons with Sambucini (2019) yield similar results.

5.2 Simulation study 2

For the motivations presented in Section 1, we evaluate the behavior of the proposed method in scenarios where, by definition, Sambucini (2019) all exhibits the same operating characteristics.

[Table 6 about here.]

Table 6 lists the operating characteristics of the proposed designs, summarized by the empirical probabilities of PET, PRN, and ASS. As expected, PET tended to decrease from scenarios 1 to 4, and PRN and ASS tend to increase. In other words, we are able to capture the structure of cases with toxicity without efficacy. For cohort size, as in the simulation study 1, PRN and ASS increase and PET decreases overall in cohort size 5 compared with cohort size 1.

6 Discussion

We proposed a new design for a Bayesian single phase II study with both efficacy and safety endpoints. Specifically, an index vector was employed that appropriately summarized the situation by considering the structure in the case where toxicity without efficacy, accounted for the uncertainty in the historical control data through the use of prior distribution. Furthermore, the operating characteristics of the proposed method were demonstrated by a comprehensive simulation study. Notably, the proposed design yielded desirable operating characteristics under various setting. Consequently, the proposed method makes appropriate interim go/no-go decision.

In Section 5, the tuning parameters were set to the same values as in Sambucini (2019) for comparison; however, the optimization of these tuning parameters will be important in the practical use. Therefore, we also illustrate the calibration of the design thresholds to ensure desirable frequentist operating characteristics under the selected scenario of interest. Similar to Yin et al. (2012), considering the null cases, all entries with type I error rates are 10% or less in our study, for which the paired values of (λ, θ_L) satisfy our requirements. Simultaneously, under the alternative cases, we need to find the paired value that provides a maximum power of more than 80%. Given that we follow the aforementioned setting of parameters with a cohort size five participants other than the pair of (λ, θ_L) , we conduct 10,000 simulated clinical trials. For each of the paired values of (λ, θ_L) , we obtain the type I error and power listed in Table 7.

[Table 7 about here.]

In this case, the type I error rate is guaranteed to be less than 0.10 except for the combinations $(\lambda, \theta_L) = (0.70, 0.001)$ and $(\lambda, \theta_L) = (0.70, 0.01)$. One of these combinations can be selected to maximize the power using the boundary line of the staircase curve. In this case, it is appropriate to set $(\lambda, \theta_L) = (0.75, 0.01)$ highlighted in gray at the time of designing a clinical trial.

Although the proposed method is considered to be a powerful method for making appropriate decisions by optimizing the tuning parameters, a few limitations exist. First, as pointed out by Saville, et al. (2014), a problem with computational burden still remains. For example, as shown in Section 2, the number of patterns increased due to the considerations of efficacy and safety, predictive probability calculation is exhaustive. To circumvent this issue, in addition to the Monte Carlo approach, we proposed an asymptotic approach and evaluated its performance. Although the performance of the asymptotic approach was good, these results were limited to our simulation pattern and thus, we should be careful about generalizing it. However, in practical use, the accuracy of the approximation to the Monte Carlo approach may not have a major impact in a well-designed the clinical trial that is based on an asymptotic approach with sound operating characteristics. Second, as explained in Section 4, the probability of success may not increase above a certain level regardless of the size of the single-arm phase II study. Depending on the accuracy, the proposed predictive probability may be saturated by the location parameter. Thus, optimization of the tuning parameter is important, and the aforementioned calibration is strongly recommended. Notably, in the Bayesian framework, the FDA (Guidance industry, 2020) also states that it is possible to use simulations to estimate the frequentist operating characteristics of power and type I error probability. It also states that decision criteria can be chosen to provide type I error control at a specified level. Additionally, the proposed method requires the use of simultaneous distribution of efficacy and toxicity. It may be more difficult to obtain historical control data compared to cases where the results are referred to as marginal distributions, i.e., aggregated data, for efficacy and toxicity. Therefore, considering the issue

of a small sample size, it is important to make an effort to access the individual patient data to mature the data when the historical control data are generally small. Further, it is desirable to elaborate on the data, e.g., by considering access to real-world data sources. Lastly, regarding the stopping boundary, although it is important that the go/no-go decision boundary can be enumerated before the onset of the trial, the proposed method can not be possible to calculate it due to its dependency on the joint structure of the interim data. This issue was also highlighted by Sambucini (2021a) as well. Thus statistician must calculate the predictive probability for each interim monitoring time point.

Regarding the interpretation of the bivariate index, as this is a new index, and no clinical results are yet available based on it, we cannot rule out the possibility that the index itself is difficult to interpret. However, in the context of the predictive probability, Saville, et al. (2014) states that clinical trial designs using predictive probability for interim monitoring do not claim efficacy using predictive probability. Rather, the claim of treatment benefit is based on either Bayesian posterior probability or frequentist criteria. Similarly, the proposed method is used only as a decision-making framework and is not intended to evaluate the magnitude of the treatment effect. In this respect, it is important to comprehensively evaluate the study results by considering, e.g., the posterior distribution of observed response rate and the frequency of adverse events of special interest.

In this paper, we evaluated the operating characteristics of cohorts one and five participants, respectively. Of course, although the performance was generally better with a cohort size of one participant, it was confirmed that the performance was not so inferior to that of five participants. On the other hand, provided that the clinical trial is statistically well designed, it is also important to preserve the study integrity in conducting clinical trials. If the cohort size is set at one participant, there is a concern that it may lead to bias in the efficacy and safety evaluation. For example, it is impossible to deny any bias that may occur when the person in charge of the study knows that the study will be stopped if only one response is obtained or if one toxicity is observed. Thus, it may be appropriate to set the cohort size to e.g., within five participants when conducting the proposed method, provided that the performance is not so inferior.

Finally, the proposed method assumes that the endpoints can be observed quickly enough, with respect to the accrual, such that adaptive go/no-go decisions can be made in a timely fashion at each interim monitoring. Thus, we could postpone the accrual at the interim to wait for the data to be cleared. However, this approach is typically infeasible in practice as repeatedly suspending patient accrual is impractical and may lead to unacceptably long trials. For example, if confirmation is required to determine the best overall response according to RECIST for efficacy evaluation, this could have led delayed response. To address such issues, Cai et al. (2014) proposed a Bayesian trial design to allow continuous monitoring of phase II clinical trials in the presence of delayed responses. Therefore, it is desirable to exploit a new design to allow for the delayed responses in the proposed design.

Author Contributions

Takuya Yoshimoto contributed to the study conception and design. The analysis was performed by Takuya Yoshimoto, and all authors checked the result. The first draft of the manuscript was written by Takuya Yoshimoto, and all authors commented on previous versions of the manuscript. All the authors have read and approved the final version of the manuscript.

Funding

This research received no specific grant from funding agencies in the public, commercial, or non-for-profit sectors.

Conflict of Interest

Takuya Yoshimoto is an employee of Chugai Pharmaceutical Co., Ltd.

Data Availability Statement

All source code can be requested from the corresponding author.

ORCID

Takuya Yoshimoto, https://orcid.org/0000-0002-8747-1395

Appendix A: Asymptotic variance-covariance matrix of bivariate index vector

Using Slutsky's theorem, given the fixed sample size of N, \sqrt{N} ($\hat{p} - p$) has asymptotically a bivariate normal distribution with zero mean and covariance matrix $\mathbf{Diag}(p)$, where \hat{p} is consistent estimator of p and $\mathbf{Diag}(p)$ is diagonal matrix with the elements of p on the main diagonal (see, e.g., Agresti, 2013, p.590). Thus, $\hat{\Phi}$ is given by Φ , where Φ_{eff} and Φ_{tox} are replaced by $\hat{\Phi}_{eff}$ and $\hat{\Phi}_{tox}$. Let $(\partial \Phi/\partial p')$ denote 2×4 matrix as follows:

$$\begin{pmatrix} \frac{\partial \mathbf{\Phi}}{\partial \mathbf{p}'} \end{pmatrix} = \begin{pmatrix} \frac{\partial \Phi_{eff}}{\partial p_{11}} & \frac{\partial \Phi_{eff}}{\partial p_{12}} & \frac{\partial \Phi_{eff}}{\partial p_{12}} & \frac{\partial \Phi_{eff}}{\partial p_{21}} & \frac{\partial \Phi_{eff}}{\partial p_{22}} \end{pmatrix}$$

$$= \begin{pmatrix} 0 & \frac{-p_{21}}{2(p_{12} + p_{21})^2 \log 2} \log \frac{p_{21}^*}{p_{21}^* + 1} & \frac{p_{12}}{2(p_{12} + p_{21})^2 \log 2} \log \frac{p_{21}^*}{p_{21}^* + 1} & 0 \\ \frac{1}{2 \log 2} \log \frac{p_{\cdot 1}}{p_{\cdot 1} + 1} & 0 & \frac{1}{2 \log 2} \log \frac{p_{\cdot 1}}{p_{\cdot 1} + 1} & 0 \end{pmatrix}.$$

When N approaches infinity, the estimated index vector can be approximated as

$$\hat{\boldsymbol{\Phi}} = \boldsymbol{\Phi} + \left(\frac{\partial \boldsymbol{\Phi}}{\partial \boldsymbol{p}'}\right) (\hat{\boldsymbol{p}} - \boldsymbol{p}) + o\left(\|\hat{\boldsymbol{p}} - \boldsymbol{p}\|\right),$$

where $o(\|\hat{\boldsymbol{p}} - \boldsymbol{p}\|)$ tends towards (0,0)'. Using the delta method (see Agresti, 2013, Section 16.1), $\sqrt{N} \left(\hat{\boldsymbol{\Phi}} - \boldsymbol{\Phi}\right)$ has an asymptotically bivariate normal distribution with zero mean and covariance matrix:

$$oldsymbol{\Sigma} = \left(rac{\partial oldsymbol{\Phi}}{\partial oldsymbol{p'}}
ight) \left(\mathbf{Diag}(oldsymbol{p}) - oldsymbol{p}oldsymbol{p'}
ight) \left(rac{\partial oldsymbol{\Phi}}{\partial oldsymbol{p'}}
ight)' = \left(egin{matrix} \sigma_{11} & \sigma_{12} \ \sigma_{21} & \sigma_{22} \end{matrix}
ight),$$

where $\sigma_{12} = \sigma_{21}$. Elements σ_{11} , σ_{12} and σ_{22} are calculated as follows:

$$\sigma_{11} = \left[\frac{1}{2 \log 2} \log \left(\frac{p_{21}^*}{p_{21}^* + 1} \right) \right]^2 \frac{p_{12}^* p_{21}^*}{p_{12} + p_{21}},$$

$$\sigma_{12} = \left(\frac{1}{2 \log 2} \right)^2 p_{12}^* p_{21}^* \log \left(\frac{p_{21}^*}{p_{21}^* + 1} \right) \log \left(\frac{p_{\cdot 1}}{p_{\cdot 1} + 1} \right),$$

$$\sigma_{22} = \left[\frac{1}{2 \log 2} \log \left(\frac{p_{\cdot 1}}{p_{\cdot 1} + 1} \right) \right]^2 p_{\cdot 1} p_{\cdot 2}.$$

In addition, based on the large-sample properties of Bayes procedures (Wasserman, 2004, Section 11.5), we can regard the above asymptotic distribution as an asymptotic posterior distribution of Φ .

Appendix B: Dirichlet compound multinomial probability mass function

Let Ω denote the sample space defined by

$$\left\{ \boldsymbol{p}_{E}; \ p_{E,ij} \in [0,1], \ i,j=1,2, \ \sum_{i} \sum_{j} p_{E,ij} = 1 \right\}.$$

With reference to Thorsén (2014), Dirichlet compound multinomial probability mass function is thoroughly calculated as follows:

$$f_{m}(\boldsymbol{y}|\boldsymbol{\alpha}_{E},\boldsymbol{x}) = \int_{\Omega} f(\boldsymbol{y}|\boldsymbol{\alpha}_{E}) f(\boldsymbol{y}|\boldsymbol{\alpha}_{E},\boldsymbol{x}) d\boldsymbol{p}_{E}$$

$$= \int_{\Omega} \frac{m!}{\prod_{i} \prod_{j} y_{ij}!} \prod_{i} \prod_{j} p_{E,ij}^{y_{ij}} \frac{\Gamma\left(\sum_{i} \sum_{j} \alpha_{E,ij} + x_{ij}\right)}{\prod_{i} \prod_{j} \Gamma\left(\alpha_{E,ij} + x_{ij}\right)} \prod_{i} \prod_{j} p_{E,ij}^{\alpha_{E,ij} + x_{ij} - 1} d\boldsymbol{p}_{E}$$

$$= \frac{m!}{\prod_{i} \prod_{j} y_{ij}!} \frac{\Gamma\left(\sum_{i} \sum_{j} \alpha_{E,ij} + x_{ij}\right)}{\prod_{i} \prod_{j} \Gamma\left(\alpha_{E,ij} + x_{ij}\right)} \int_{\Omega} \prod_{i} \prod_{j} p_{E,ij}^{\alpha_{E,ij} + x_{ij} + y_{ij} - 1} d\boldsymbol{p}_{E}.$$

We then consider a Dirichlet distribution with parameter $\alpha_E + x + y$. From the normalization constant, we obtain

$$\int_{\Omega} \prod_{i} \prod_{j} p_{E,ij}^{\alpha_{E,ij} + x_{ij} + y_{ij} - 1} d\boldsymbol{p}_{E} = \frac{\prod_{i} \prod_{j} \Gamma\left(\alpha_{E,ij} + x_{ij} + y_{ij}\right)}{\Gamma\left(\sum_{i} \sum_{j} \alpha_{E,ij} + x_{ij} + y_{ij}\right)}.$$

Accordingly, we can obtain the following Dirichlet compound multinomial probability mass function:

$$f_m(\boldsymbol{y}|\boldsymbol{\alpha}_E,\boldsymbol{x}) = \frac{\Gamma(m+1)}{\prod_i \prod_j \Gamma(y_{ij}+1)} \frac{\Gamma\left(\sum_i \sum_j \alpha_{E,ij} + x_{ij}\right)}{\Gamma\left(\sum_i \sum_j \alpha_{E,ij} + x_{ij} + y_{ij}\right)} \prod_i \prod_j \frac{\Gamma\left(\alpha_{E,ij} + x_{ij} + y_{ij}\right)}{\Gamma\left(\alpha_{E,ij} + x_{ij}\right)}.$$

References

- [1] Agresti, A. (2013). Categorical data analysis, 3rd edition. Wiley, New Jersey.
- [2] Berger, J. O. and Bernardo, J. M. (1992). Ordered group reference priors with application to the multinomial problem. *Biometrika*, **79**(1), 25-37.
- [3] Berry, D. A. (2004). Bayesian statistics and the efficiency and ethics of clinical trials. *Statistical Science*. **19**(1), 175-187.
- [4] Brutti, P., Gubbiotti, S. and Sambucini, V. (2011). An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials. *Statistics in Medicine*, **30**(14), 1648-1664.
- [5] Bryant, J. and Day, R. (1995). Incorporating toxicity considerations into the design of two-stage phase II clinical trials. *Biometrics*, 51(4), 1372-1383.
- [6] Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., Cristofanilli, M., Frye, D. K., Smith, T. L., Hunt, K. K., Singletary, S. E., Sahin, A. A., Ewer, M. S., Buchholz, T. A., Berry, D. and Hortobagyi, G. N. (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Journal of Clinical Oncology, 23(16), 3676-3685.
- [7] Cai, C., Liu, S. and Yuan, Y. (2014). A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. *Statistics in Medicine*, **33**(23), 4017-4028.
- [8] Domchek, S. M., Postel-Vinay, S., Im S. A., Park, Y. H., Delord, J. P., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M. G., Wang, D., Waqar, S. N., Lanasa, M., Rhee, J., Gao, H., Rocher-Ros, V., Jones, E. V., Gulati, S., Coenen-Stass, A., Kozarewa, I., Lai, Z., Angell, H. K., Opincar, L., Herbolsheimer, P. and Kaufman, B. (2020). Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. The LANCET Oncology, 21(9), 1155-1164.
- [9] Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228-247.
- [10] Fujikawa, K., Teramukai, S., Yokota, I. and Daimon, T. (2019). A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability. *Biometrical Journal*, **62**(2), 330-338.
- [11] Green, S., Benedetti, J., Smith, A. and Crowley, J. (2012). Clinical trials in oncology, 3rd edition. CRC Press, Florida.
- [12] Guo, B. and Liu, S. (2020). An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints. *Biometrical Journal*, **62**(2), 339-349.
- [13] Hankin, R. K. S. (2007). Urn sampling without replacement: enumerative combinatorics in R. *Journal of Statistical Software*, **17**(1), 1-6.

- [14] Hirakawa, A., Nishikawa, T., Yonemori, K., Shibata, T., Nakamura, K., Ando, M., Ueda, T., Ozaki, T., Tamura, K., Kawai, A. and Fujiwara, Y. (2018). Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: A case study of phase 2 trial for sarcoma. Therapeutic Innovation & Regulatory Science, 52(3), 334-338.
- [15] Hobbs, B. P., Chen, N. and Lee, J. J. (2018). Controlled multi-arm platform design using predictive probability. *Statistical Methods in Medical Research*, **27**(1), 65-78.
- [16] Lee, J. J. and Liu, D. D. (2008). A predictive probability design for phase II cancer clinical trials. *Clinical Trials*, **5**(2), 93-106.
- [17] Lin, J. (1991). Divergence measures based on the Shannon entropy. *IEEE Transactions on Information Theory*, **37**(1), 145-151.
- [18] Murai, K., Ureshino, H., Kumagai, T., Tanaka, H., Nishiwaki, K., Wakita, S., Inokuchi, K., Fukushima, T., Yoshida, C., Uoshima, N., Kiguchi, T., Mita, M., Aoki, J., Kimura, S., Karimata, K., Usuki, K., Shimono, J., Chinen, Y., Kuroda, J., Matsuda, Y., Nakao, K., Ono, T., Fujimaki, K., Shibayama, H., Mizumoto, C., Takeoka, T., Io, K., Kondo, T., Miura, M., Minami, Y., Ikezoe, T., Imagawa, J., Takamori, A., Kawaguchi, A., Sakamoto, J. and Kimura, S. (2021). Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. The Lancet Haematology. 8(12), 902-911.
- [19] R Core Team (2023). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
- [20] Ruberg, S.J., Beckers, F., Hemmings, R., Honig, P., Irony, T., LaVange, L., Lieberman, G., Mayne, J. and Moscicki, R. (2023). Application of Bayesian approaches in drug development: starting a virtuous cycle. *Nature Reviews Drug Discovery*, 22, 235-250.
- [21] Sambucini, V. (2019). Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials. *Computational Statistics & Data Analysis*, **132**, 18-30.
- [22] Sambucini, V. (2021a). Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials. *Statistical Methods & Applications*, **30**(2), 637-663.
- [23] Sambucini, V. (2021b). Bayesian sequential monitoring of single-arm trials: a comparison of futility rules based on binary data. *International Journal of Environmental Research and Public Health*. 18(16), 8816.
- [24] Saville, B. R., Connor, J. T., Ayers, G. D. and Alvarez, J. (2014). The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. *Clinical Trials*, **11**(4), 485-493.
- [25] Shah, M., Rahman. A., Theoret, M. R. and Pazdur, R. (2021). The drug-dosing conundrum in oncology when less is more. *New England Journal of Medicine*. **385**(16), 1445-1447.
- [26] Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. *Controlled Clinical Trials*, **10**(1), 1-10.
- [27] Spiegelhalter, D. J., Abrams, K. R. and Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley, New York.

- [28] Tap, W. D., Demetri, G., Barnette, P., Desai, J., Kavan, P., Tozer, R., Benedetto, P. W., Friberg, G., Deng, H., McCaffery, I., Leitch, I., Badola, S., Chang, S., Zhu, M. and Tolcher, A. (2012). Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. *Journal of Clinical Oncology.* 30(15), 1849-1856.
- [29] Thall, P. F. and Simon, R. (1994a). Practical Bayesian guidelines for phase IIB clinical trials. Biometrics, 50(2), 337-349.
- [30] Thall, P. F. and Simon, R. (1994b). A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. *Controlled Clinical Trials*, **15**(6), 463-481.
- [31] Thall, P. F., Simon, R. M. and Estey, E. H. (1995). Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. *Statistics in Medicine*, **14**(4), 357-379.
- [32] Thorsén, E. (2014). Multinomial and Dirichlet-multinomial modeling of categorical time series. https://www2.math.su.se/matstat/reports/seriec/2014/rep6/report.pdf.
- [33] US Food and Drug Administration. (2020). Guidance for industry: Interacting with the FDA on complex innovative trial designs for drugs and biological products.
- [34] US Food and Drug Administration. (2023). Draft Guidance for industry: Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases.
- [35] Wasserman, L. (2004). All of statistics: a concise course in statistical inference. Springer, New York.
- [36] Yin, G., Chen, N. and Lee, J. J. (2012). Phase II trial design with Bayesian adaptive randomization and predictive probability. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*. 61(2), 219-235.
- [37] Zhou, H., Lee, J. J. and Yuan, Y. (2017). BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. *Statistics in Medicine*, **36**(21), 3302-3314.
- [38] Zohar, S., Teramukai, S. and Zhou, Y. (2008). Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. *Contemporary Clinical Trials*, **29**(4), 608-616.

Table 1: Artificial data on efficacy and toxicity in the interim stage.

(a) Toxicity Efficacy YesNo Total 15 5 Yes 10 No 0 10 10 5 20 25 Total

(b)								
	Toxi	Toxicity						
Efficacy	Yes	No	Total					
Yes	0	10	10					
No	5	10	15					
Total	5	20	25					

Table 2: Square contingency table with binary endpoints representing efficacy and toxicity.

	Tox		
Efficacy	Yes	No	Total
Yes	p_{11}	p_{12}	p_1 .
No	p_{21}	p_{22}	p_2 .
Total	$p_{\cdot 1}$	$p_{\cdot 2}$	1

Table 3: Detailed calculations to obtain the predictive probability by using the Monte Carlo approach with the 10,000 times repeated simulations when $\alpha_E = (0.5, 0.5, 0.5, 0.5)$, $\alpha_S = (10, 9, 11, 30)$, x = (5, 10, 0, 10), $\lambda = 0.80$, $N_{max} = 30$.

y	$f_m(oldsymbol{y} oldsymbol{lpha}_E,oldsymbol{x})$	$B(\boldsymbol{Y})$	$I(B(\boldsymbol{Y}) > \lambda)$	y	$f_m(oldsymbol{y} oldsymbol{lpha}_E,oldsymbol{x})$	$B(\boldsymbol{Y})$	$I(B(\boldsymbol{Y}) > \lambda)$
(5,0,0,0)	0.0010619	0.5284	0	(1, 2, 1, 1)	0.0102602	0.8533	1
(4, 1, 0, 0)	0.0058683	0.6469	0	(0, 3, 1, 1)	0.0077729	0.9129	1
(3, 2, 0, 0)	0.0158789	0.7551	0	(2,0,2,1)	0.0004142	0.6377	0
(2,3,0,0)	0.0264649	0.8508	1	(1, 1, 2, 1)	0.0013383	0.7671	0
(1,4,0,0)	0.0274828	0.9138	1	(0, 2, 2, 1)	0.0013991	0.8443	1
(0, 5, 0, 0)	0.0144909	0.9574	1	(1,0,3,1)	0.0001062	0.6508	0
(4,0,1,0)	0.0002794	0.5366	0	(0, 1, 3, 1)	0.0002028	0.7461	0
(3, 1, 1, 0)	0.0013808	0.6548	0	(0,0,4,1)	0.0000169	0.6464	0
(2, 2, 1, 0)	0.0031758	0.7649	0	(3,0,0,2)	0.0158789	0.7551	0
(1, 3, 1, 0)	0.0040715	0.8435	1	(2, 1, 0, 2)	0.0666916	0.8419	1
(0,4,1,0)	0.0024984	0.9101	1	(1, 2, 0, 2)	0.1179928	0.9145	1
(3,0,2,0)	0.0000986	0.5268	0	(0, 3, 0, 2)	0.0893885	0.9562	1
(2, 1, 2, 0)	0.0004142	0.6387	0	(2,0,1,2)	0.0031758	0.7643	0
(1, 2, 2, 0)	0.0007329	0.7556	0	(1, 1, 1, 2)	0.0102602	0.8531	1
(0, 3, 2, 0)	0.0005552	0.8441	1	(0, 2, 1, 2)	0.0107266	0.9165	1
(2,0,3,0)	0.0000329	0.5395	0	(1,0,2,2)	0.0007329	0.7546	0
(1, 1, 3, 0)	0.0001062	0.6528	0	(0, 1, 2, 2)	0.0013991	0.8437	1
(0, 2, 3, 0)	0.0001110	0.7598	0	(0,0,3,2)	0.0001110	0.7558	0
(1,0,4,0)	0.0000089	0.5334	0	(2,0,0,3)	0.0264649	0.8507	1
(0, 1, 4, 0)	0.0000169	0.6495	0	(1, 1, 0, 3)	0.0855020	0.9148	1
(0,0,5,0)	0.0000014	0.5246	0	(0, 2, 0, 3)	0.0893885	0.9562	1
(4,0,0,1)	0.0058683	0.6469	0	(1,0,1,3)	0.0040715	0.8428	1
(3, 1, 0, 1)	0.0289963	0.7623	0	(0, 1, 1, 3)	0.0077729	0.9123	1
(2, 2, 0, 1)	0.0666916	0.8419	1	(0,0,2,3)	0.0005552	0.8404	1
(1, 3, 0, 1)	0.0855020	0.9149	1	(1,0,0,4)	0.0274828	0.9137	1
(0,4,0,1)	0.0524672	0.9575	1	(0, 1, 0, 4)	0.0524672	0.9574	1
(3,0,1,1)	0.0013808	0.6548	0	(0,0,1,4)	0.0024984	0.9088	1
(2, 1, 1, 1)	0.0057993	0.7600	0	(0,0,0,5)	0.0144909	0.9573	1

Table 4: Detailed calculations to obtain the predictive probability using the asymptotic approach when $\alpha_E = (0.5, 0.5, 0.5, 0.5), \ \alpha_S = (10, 9, 11, 30), \ \boldsymbol{x} = (5, 10, 0, 10), \ \lambda = 0.80, \ N_{max} = 30.$

y	$f_m(oldsymbol{y} oldsymbol{lpha}_E,oldsymbol{x})$	$B(\boldsymbol{Y})$	$I(B(\boldsymbol{Y}) > \lambda)$	y	$f_m(oldsymbol{y} oldsymbol{lpha}_E,oldsymbol{x})$	$B(\boldsymbol{Y})$	$I(B(\boldsymbol{Y}) > \lambda)$
(5,0,0,0)	0.0010619	0.5239	0	(1, 2, 1, 1)	0.0102602	0.8384	1
(4, 1, 0, 0)	0.0058683	0.6415	0	(0, 3, 1, 1)	0.0077729	0.9066	1
(3, 2, 0, 0)	0.0158789	0.7490	0	(2,0,2,1)	0.0004142	0.6393	0
(2,3,0,0)	0.0264649	0.8388	1	(1, 1, 2, 1)	0.0013383	0.7470	0
(1,4,0,0)	0.0274828	0.9069	1	(0, 2, 2, 1)	0.0013991	0.8370	1
(0, 5, 0, 0)	0.0144909	0.9530	1	(1,0,3,1)	0.0001062	0.6365	0
(4,0,1,0)	0.0002794	0.5235	0	(0, 1, 3, 1)	0.0002028	0.7442	0
(3, 1, 1, 0)	0.0013808	0.6412	0	(0,0,4,1)	0.0000169	0.6320	0
(2, 2, 1, 0)	0.0031758	0.7487	0	(3,0,0,2)	0.0158789	0.7489	0
(1, 3, 1, 0)	0.0040715	0.8386	1	(2,1,0,2)	0.0666916	0.8388	1
(0,4,1,0)	0.0024984	0.9067	1	(1, 2, 0, 2)	0.1179928	0.9069	1
(3,0,2,0)	0.0000986	0.5227	0	(0, 3, 0, 2)	0.0893885	0.9530	1
(2,1,2,0)	0.0004142	0.6403	0	(2,0,1,2)	0.0031758	0.7479	0
(1, 2, 2, 0)	0.0007329	0.7479	0	(1, 1, 1, 2)	0.0102602	0.8380	1
(0, 3, 2, 0)	0.0005552	0.8378	1	(0, 2, 1, 2)	0.0107266	0.9063	1
(2,0,3,0)	0.0000329	0.5212	0	(1,0,2,2)	0.0007329	0.7454	0
(1, 1, 3, 0)	0.0001062	0.6387	0	(0, 1, 2, 2)	0.0013991	0.8357	1
(0, 2, 3, 0)	0.0001110	0.7462	0	(0,0,3,2)	0.0001110	0.7408	0
(1,0,4,0)	0.0000089	0.5187	0	(2,0,0,3)	0.0264649	0.8388	1
(0, 1, 4, 0)	0.0000169	0.6359	0	(1, 1, 0, 3)	0.0855020	0.9069	1
(0,0,5,0)	0.0000014	0.5148	0	(0, 2, 0, 3)	0.0893885	0.9529	1
(4,0,0,1)	0.0058683	0.6414	0	(1,0,1,3)	0.0040715	0.8373	1
(3, 1, 0, 1)	0.0289963	0.7489	0	(0, 1, 1, 3)	0.0077729	0.9058	1
(2, 2, 0, 1)	0.0666916	0.8388	1	(0,0,2,3)	0.0005552	0.8334	1
(1, 3, 0, 1)	0.0855020	0.9069	1	(1,0,0,4)	0.0274828	0.9068	1
(0,4,0,1)	0.0524672	0.9530	1	(0, 1, 0, 4)	0.0524672	0.9529	1
(3,0,1,1)	0.0013808	0.6408	0	(0,0,1,4)	0.0024984	0.9048	1
(2, 1, 1, 1)	0.0057993	0.7484	0	(0,0,0,5)	0.0144909	0.9529	1

Table 5: Description of the scenarios of interest and the probability of early termination (PET), the percentage of rejecting the null hypothesis (PRN), and the average sample size (ASS) when $\alpha_E = (0.5, 0.5, 0.5, 0.5)$, $\alpha_S = (30, 60, 30, 80)$, $\lambda = 0.80$, $\theta_L = 0.001$, $N_{min} = 10$, $N_{max} = 40$ with 10,000 simulated trials.

		Cohort size: 1 participant			Cohort size: 5 participants		
Scenario	\boldsymbol{p}_E	PET	PRN	ASS	PET	PRN	ASS
1.	(0.15, 0.30, 0.15, 0.40)	0.9292	0.0550	25.0649	0.8287	0.0531	27.3005
2.	(0.15, 0.30, 0.20, 0.35)	0.9793	0.0146	20.9999	0.9403	0.0139	23.0835
3.	(0.20, 0.25, 0.15, 0.40)	0.9815	0.0121	20.9437	0.9364	0.0135	23.1800
4.	(0.20, 0.20, 0.10, 0.50)	0.9422	0.0424	24.3711	0.8490	0.0407	26.5900
5.	(0.15, 0.15, 0.15, 0.55)	0.9864	0.0087	20.0937	0.9440	0.0082	22.4240
6.	(0.18, 0.42, 0.02, 0.38)	0.3810	0.5863	36.6277	0.2618	0.5858	37.3565
7.	(0.18, 0.46, 0.02, 0.34)	0.3758	0.5937	36.7275	0.2540	0.5938	37.4615
8.	(0.15, 0.45, 0.02, 0.38)	0.2124	0.7645	38.3488	0.1328	0.7695	38.7730
9.	(0.10, 0.50, 0.05, 0.35)	0.1327	0.8486	39.0428	0.0745	0.8533	39.3100
10.	(0.10, 0.55, 0.05, 0.30)	0.1246	0.8592	39.1270	0.0693	0.8649	39.3545


Table 6: Description of the scenarios of interest assumed with various true no efficacy and toxicity and the probability of early termination (PET), the percentage of rejecting the null hypothesis (PRN), and the average sample size (ASS) when $\alpha_E = (0.5, 0.5, 0.5, 0.5, 0.5)$, $\alpha_S = (30, 60, 30, 80)$, $\lambda = 0.80$, $\theta_L = 0.001$, $N_{min} = 10$, $N_{max} = 40$ with 10,000 simulated trials.

		Cohort size: 1 participant			Cohort size: 5 participants		
Scenario	\boldsymbol{p}_E	PET	PRN	ASS	PET	PRN	ASS
1.	(0.15, 0.30, 0.20, 0.35)	0.9813	0.0145	20.8878	0.9408	0.0134	22.9910
2.	(0.19, 0.30, 0.16, 0.35)	0.9764	0.0181	21.6474	0.9305	0.0178	23.6330
3.	(0.23, 0.30, 0.12, 0.35)	0.9707	0.0217	22.2601	0.9189	0.0232	24.2165
4.	(0.27, 0.30, 0.08, 0.35)	0.9667	0.0264	22.8911	0.9223	0.0261	24.6960
5.	(0.31, 0.30, 0.04, 0.35)	0.9570	0.0325	23.1372	0.9121	0.0286	24.8230


Table 7: Type I error and power values under the null hypothesis and alternative hypothesis by varying the design parameter (λ, θ_L) when $P_E = (0.15, 0.30, 0.15, 0.40)$ under H_0 , $P_E = (0.10, 0.50, 0.05, 0.35)$ under H_1 , $\alpha_E = (0.5, 0.5, 0.5, 0.5, 0.5)$, $\alpha_S = (30, 60, 30, 80)$, $N_{min} = 10$, $N_{max} = 40$, cohort size equals to 5 participants with 10,000 simulated trials.

$\overline{ heta_L}$	Null hypothesis with λ					Alternative hypothesis with λ				λ
	0.70	0.75	0.80	0.85	0.90	0.70	0.75	0.80	0.85	0.90
0.001	0.1146	0.0852	0.0578	0.0355	0.0179	0.9238	0.9137	0.8558	0.8226	0.7115
0.01	0.1099	0.0813	0.0508	0.0355	0.0170	0.9212	0.9150	0.8484	0.8100	0.7145
0.05	0.0967	0.0760	0.0492	0.0321	0.0169	0.8970	0.8902	0.8227	0.7806	0.6775
0.10	0.0909	0.0717	0.0451	0.0285	0.0139	0.8733	0.8659	0.7827	0.7501	0.6393

Figure 1: Posterior distribution using Monte Carlo approach with the 10,000 times repeat simulations when $\alpha_E = (0.5, 0.5, 0.5, 0.5, 0.5)$, $\alpha_S = (10, 9, 11, 30)$, x = (5, 10, 0, 10), y = (0, 3, 2, 0), $N_{max} = 30$. (a) illustrates Φ_t for t = E, S and (b) illustrates the difference distribution $\Phi_E - \Phi_S$. E and S represent experimental and standard treatments, respectively.




(a) Simulation distribution of Φ_E and Φ_S




(b) Simulation distribution of $\Phi_E - \Phi_S$

Figure 2: Posterior distribution using asymptotic approach when $\alpha_E = (0.5, 0.5, 0.5, 0.5)$, $\alpha_S = (10, 9, 11, 30)$, $\boldsymbol{x} = (5, 10, 0, 10)$, $\boldsymbol{y} = (0, 3, 2, 0)$, $N_{max} = 30$. (a) illustrates $\boldsymbol{\Phi}_t$ for t = E, S and (b) illustrates the difference distribution $\boldsymbol{\Phi}_E - \boldsymbol{\Phi}_S$. E and S represent experimental treatment and treatments, respectively.




(a) Asymptotic distribution of $\boldsymbol{\Phi}_E$ and $\boldsymbol{\Phi}_S$




(b) Asymptotic distribution of $\Phi_E - \Phi_S$

Figure 3: The predictive probability under various setting when $P_E = (0.15, 0.30, 0.15, 0.40)$ under H_0 , $P_E = (0.10, 0.50, 0.05, 0.35)$ under H_1 , $\alpha_E = (0.5, 0.5, 0.5, 0.5)$, $\lambda = 0.80$ and m = 20. (a) and (b) illustrate the predictive probability under H_0 and H_1 , respectively. E and S represent experimental and standard treatments, respectively.



(a) Predictive probability under H_0



(b) Predictive probability under H_1